Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00306202 · OUTCOME

Number of Participants With Molecular Responses in Stratum 1 (Ph+ CP-CML)

Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia · Source last updated 2021-02-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
At baseline (within 3 weeks before initiation of study therapy), After hematologic response, EOT (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63])

What was measured

Molecular response was calculated by measuring p210 variant of BCR-ABL transcripts in blood during treatment using quantitative polymerase chain reaction (qPCR) assay. Major molecular response (MMR): Ratio of the BCR-ABL to ABL \<10\^-3 or 0.1% on the international scale. Complete molecular response (CMR): Complete absence of BCR-ABL or the ratio is \<10\^-4.5 or 0.00316% on the international scale. Confirmed MMR or CMR = Criteria met again \>6 weeks. BCR-ABL=the fused gene found in participants with this type of CML.

Analysis population: All treated participants in stratum 1: Participants who received at least 1 dose of study therapy.

Groups in this outcome

Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2)

Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP). Dasatinib 60 mg/m\^2 QD, as long as clinical benefit was maintained.

Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2)

Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP). Dasatinib 80 mg/m\^2 QD, as long as clinical benefit was maintained.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2)11
Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2)6

Reported measurements

MMR (Overall)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2)6Not reportedNot reportedNot reportedNot reported
Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2)2Not reportedNot reportedNot reportedNot reported
CMR (Unconfirmed)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2)3Not reportedNot reportedNot reportedNot reported
Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2)1Not reportedNot reportedNot reportedNot reported
CMR (Confirmed)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2)1Not reportedNot reportedNot reportedNot reported
Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2)0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        6
      2. group Id
        OG001
        value
        2
    title
    MMR (Overall)
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        3
      2. group Id
        OG001
        value
        1
    title
    CMR (Unconfirmed)
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        0
    title
    CMR (Confirmed)
denoms
  1. counts
    1. group Id
      OG000
      value
      11
    2. group Id
      OG001
      value
      6
    units
    Participants
description
Molecular response was calculated by measuring p210 variant of BCR-ABL transcripts in blood during treatment using quantitative polymerase chain reaction (qPCR) assay. Major molecular response (MMR): Ratio of the BCR-ABL to ABL \<10\^-3 or 0.1% on the international scale. Complete molecular response (CMR): Complete absence of BCR-ABL or the ratio is \<10\^-4.5 or 0.00316% on the international scale. Confirmed MMR or CMR = Criteria met again \>6 weeks. BCR-ABL=the fused gene found in participants with this type of CML.
groups
  1. description
    Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP). Dasatinib 60 mg/m\^2 QD, as long as clinical benefit was maintained.
    id
    OG000
    title
    Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2)
  2. description
    Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP). Dasatinib 80 mg/m\^2 QD, as long as clinical benefit was maintained.
    id
    OG001
    title
    Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2)
param Type
NUMBER
population Description
All treated participants in stratum 1: Participants who received at least 1 dose of study therapy.
reporting Status
POSTED
time Frame
At baseline (within 3 weeks before initiation of study therapy), After hematologic response, EOT (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63])
title
Number of Participants With Molecular Responses in Stratum 1 (Ph+ CP-CML)
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice